ALCOHOL: its metabolism and interaction with nutrients.

Area of Science:

• Hepatology
• Biochemistry
• Toxicology

Background:

• Alcoholic liver disease (ALD) is now recognized as directly hepatotoxic, independent of dietary deficiencies.
• Alcohol metabolism via cytochrome P4502E1 (CYP2E1) generates oxidative stress, contributing to liver damage.
• ALD disrupts nutrient activation, altering nutritional requirements, such as the need for S-adenosylmethionine (SAMe).

Purpose of the Study:

• To investigate the therapeutic potential of S-adenosylmethionine (SAMe) and polyenylphosphatidylcholine (PPC) in mitigating alcohol-induced liver injury.
• To explore the mechanisms by which SAMe and PPC counteract alcohol's hepatotoxicity.

Main Methods:

• Administration of SAMe in baboons to assess effects on mitochondrial lesions and glutathione levels.
• Clinical evaluation of SAMe in patients with Child A or B cirrhosis.
• Administration of PPC (and DLPC) in baboons to evaluate its impact on CYP2E1 activity, oxidative stress, and fibrosis.
• Assessment of PPC's effects on hepatic stellate cell activity and collagenase activity.

Main Results:

• SAMe attenuated mitochondrial damage, replenished glutathione, and reduced mortality in cirrhotic patients.
• PPC (and DLPC) down-regulated CYP2E1, reduced oxidative stress, deactivated hepatic stellate cells, and increased collagenase activity in baboons.
• PPC prevented ethanol-induced septal fibrosis and cirrhosis in baboons.

Conclusions:

• SAMe is a crucial supplement for patients with significant liver disease due to impaired methionine activation.
• PPC effectively counteracts major toxic effects of alcohol, offering a potential therapeutic strategy for ALD.
• Further clinical trials are warranted to confirm the efficacy of PPC in human ALD.